Table 3.
Associations between baseline biomarkers and progression-free survival and overall survival
| N |
Overall survival (adjusted for treatment only) |
Overall survival (adjusted for treatment and baseline characteristics*) |
PFS (adjusted for treatment only) |
||||||
|---|---|---|---|---|---|---|---|---|---|
| Deaths | HR (95% CI) | p value | HR (95% CI) | p value | PFS events | HR (95% CI) | p value | ||
| CEA (μg/L)/10 | 123 | 99 | 1·03 (1·01–1·04) | <0·001 | 1·03 (1·02–1·05) | <0·001 | 115 | 1·03 (1·01–1·04) | 0·001 |
| CA19-9 (IU/mL)/10 000 | 118 | 97 | 1·03 (1·01–1·05) | 0·02 | 1·03 (1·01–1·05) | 0·03 | 110 | 1·24 (1·04–1·50) | 0·02 |
| CA125 (IU/mL)/100 | 110 | 88 | 1·05 (1·01–1·10) | 0·03 | 1·08 (1·03–1·13) | 0·001 | 103 | 1·08 (1·03–1·13) | 0·001 |
| Total CK18 (M65; U/L)/100 | 119 | 97 | 1·03 (1·00–1·05) | 0·03 | 1·04 (1·01–1·06) | 0·005 | 112 | 1·02 (1·00–1·04) | 0·06 |
| CTC count (cells per 7·5 mL) | 95 | 76 | 1·05 (1·02–1·09) | 0·001 | 1·06 (1·02–1·11) | 0·002 | 89 | 1·04 (1·01–1·07) | 0·01 |
| VEGFR2 (pg/mL)/1000 | 117 | 96 | 1·07 (0·99–1·16) | 0·09 | 1·10 (1·01–1·20) | 0·02 | 110 | 1·04 (0·96–1·12) | 0·34 |
PFS=progression-free survival. HR=hazard ratio. CTC=circulating tumour cell. The /XX shows the per unit increase; for example, for CEA for every 10 μg/L increase, the hazard increases by 3% (HR 1·03).
*
Baseline characteristics: age, sex, Eastern Cooperative Oncology Group, primary site, stage, previous treatment.